Filing excerpt
Announced a definitive agreement with PepStar Therapeutics Limited (“PepStar”), a privately held, clinical-stage biotechnology company, to acquire PepStar’s oral IL-23R inhibitor program.
Source: Autobound Signal API · 68 signals tracked for Gilead · updated
Get Gilead's live signals in Claude or ChatGPT, or by API
What changed at Gilead this week? Use Autobound signals for gilead.com.Gilead announced a definitive agreement to acquire the oral IL-23R inhibitor program from PepStar Therapeutics Limited, including lead asset HCXT-2001.
Filing excerpt
Announced a definitive agreement with PepStar Therapeutics Limited (“PepStar”), a privately held, clinical-stage biotechnology company, to acquire PepStar’s oral IL-23R inhibitor program.
What this signalsIntegration work after a deal often opens needs for new systems and services.
sec-8kacquisitionAnnouncedGet every 8-K signal for Gilead and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/164b13a2-9cbb-4308-976c-17a79992f2f2 returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.
{
"signal_id": "164b13a2-9cbb-4308-976c-17a79992f2f2",
"signal_type": "sec-8k",
"signal_subtype": "acquisitionAnnounced",
"detected_at": "2026-11-03T07:08:14.975+00:00",
"company": {
"name": "Gilead",
"domain": "gilead.com"
},
"data": {
"detail": "Gilead announced a definitive agreement to acquire the oral IL-23R inhibitor program from PepStar Therapeutics Limited, including lead asset HCXT-2001. This acquisition may drive integration needs and clinical research outsourcing opportunities.",
"summary": "Gilead Enters Definitive Agreement to Acquire PepStar's Oral IL-23R Inhibitor Program",
"excerpts": "Announced a definitive agreement with PepStar Therapeutics Limited (“PepStar”), a privately held, clinical-stage biotechnology company, to acquire PepStar’s oral IL-23R inhibitor program.",
"relevance": 0.85,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000037/gild-20261029.htm",
"filing_date": "2026-10-29",
"filing_year": 2026,
"fiscal_year_end": "10/29",
"sales_relevance": "Integration needs coming",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/164b13a2-9cbb-4308-976c-17a79992f2f2 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.